Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $129

Benzinga Newsdesk www.benzinga.com Positive 91.7%

Neg 0% Neu 0% Pos 91.7%

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $112 to $129.